Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis

Lancet

Volumn 351, Issue 9103, 1998, Pages 629-632

  Passalacqua, Giovanni ^a   Albano, Monica ^a   Fregonese, Laura ^a   Riccio, Annamaria ^a   Pronzato, Caterina ^a   Mela, Giuseppe Sandro ^a   Canonica, Giorgio Walter ^a,b  

^a UNIVERSITY OF GENOA   (Italy)

^b DIMI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; EOSINOPHIL CATIONIC PROTEIN; INTERCELLULAR ADHESION MOLECULE 1;

ADOLESCENT; ADULT; ARTICLE; CELL INFILTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATOPHAGOIDES PTERONYSSINUS; DOUBLE BLIND PROCEDURE; EPITHELIUM CELL; FEMALE; HUMAN; IMMUNOTHERAPY; INFLAMMATORY CELL; MALE; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT ALLERGY; RHINOCONJUNCTIVITIS; SCORING SYSTEM; SYMPTOM; TOPICAL DRUG ADMINISTRATION; WINTER;

EID: 0032574206     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)07055-4     Document Type: Article

References (20)

1. 1 Passalacqua G, Canonica GW. Alternative routes for allergen specific immunotherapy. J Invest Allergol Clin Immunol 1996; 6: 81-87.
2. 2 Malling HJ, Weeke B. EAACI Immunotherapy position paper. Allergy 1993; 48: 1-81.
3. 3 Tari MG, Mancino M, Monti G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite: a double blind study. Allergol Immunopathol 1990; 18: 277-84.
4. 4 Feliziani V, Lattuada G, Parmiani S, Dall'Aglio PP. Safety and efficacy of sublingual rush immunotherapy with grass allergen extracts: a double blind study. Allergol Immunopathol 1995; 23: 173-78.
5. 5 Sabbah A, Hassoun S, Le Sellin J, Andre C, Sicard H. A double blind placebo controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract. Allergy 1994; 49: 309-13.
6. 6 Troise C, Voltolini S, Canessa A, Pecora S, Negrini AC. Sublingual immunotherapy in parietaria pollen induced rhinitis: a double blind study. J Invest Allergol Clin Immunol 1995; 5: 25-30.
7. 7 Giovane A, Bardare M, Passalacqua G, et al. A three year double blind placebo-controlled study with specific oral immunotherapy to Dermatophagoides: evidence of safety and efficacy in pediatric patients. Clin Exp Allergy 1994; 24: 53-59.
8. 8 Cooper PJ, Darbyshire J, Nunn AJ, Warner JO. A controlled trial of oral hyposensitization in pollen asthma and rhinitis in children. Clin Allergy 1984; 14: 541-50.
9. 9 Taudorf E, Lanner A, Laursen L, Bjorksten B, Dreborg S, Weeke B. Specific IgG IgE and IgA antibody response to oral immunotherapy in birth pollenosis. J Allergy Clin Immunol 1989; 83: 589-94.
10. 10 Holt PG. A potential vaccine strategy for asthma and allied atopic diseases during childhood. Lancet 1994; 344: 456-58.
11. 11 Bagnasco M, Mariani G, Passalacqua G, et al. Absorption and distribution kinetics of the major Parietaria judaica allergen (Par j 1) administered by noninjectable routes to healthy human beings. J Allergy Clin Immunol 1997; 100: 121-29.
12. 12 Ciprandi G, Buscaglia S, Pesce GP, Villaggio B, Bagnasco M, Canonica GW. Allergic subjects express ICAM-1 on epithelial cells of conjunctiva after allergen challenge. J Allergy Clin Immunol 1993; 91: 783-92.
13. 13 Ciprandi G, Pronzato C, Ricca V, Passalacqua G, Bagnasco M, Canonica GW. Allergen specific challenge induces ICAM1 expression on nasal epithelial cells in allergic subjects: relationships with early and late phase events. Am Rev Respir Dis 1994; 150: 1653-59.
14. 14 Ciprandi G, Buscaglia S, Pesce GP, et al. Minimal persistent inflammation is present at mucosal level in asymptomatic rhinitic patients with allergy due to mites. J Allergy Clin Immunol 1995; 96: 971-79.
15. 15 Passalacqua G, Albano M, Ruffoni S, et al. Local nasal immunotherapy to parietaria: evidence of reduction of allergic inflammation. Am J Respir Crit Care Med 1995; 152: 461-66.
16. 16 Mistrello G, Brenna O, Roncarolo D, Zanoni D, Gentili M, Falagiani P. Monomeric chemically modified allergens: immunologic and physicochemical characterization. Allergy 1996; 51: 8-15.
17. 17 Cordell JL, Falini B, Erber WN, et al. Immunoenzymatic labelling of monoclonal antibodies using immunocomplexes of alkaline phosphatase and monoclonal anti alkaline phosphatase (APAAP complexes). J Hystochem Cytochem 1984; 32: 219-45.
18. 18 Hamid QA, Schotman E, Jacobson RM, Walker SM, Durham SR. Increases in interleukin 12 messenger RNA+ cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy. J Allergy Clin Immunol 1997; 99: 254-60.
19. 19 Rak S, Hakanson L, Venge P. Immunotherapy abrogates the generation of eosinophil and neutrophil chemotactic activity. J Allergy Clin Immunol 1990; 86: 706-11.
20. 20 Secrist H, Chelen CJ, Wen Y, Marshall JD, Umetsu DT. Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals. J Exp Med 1993; 178: 2123-30.